A -- Centralized Service Facility for the In Vitro Testing of Candidate SMA Compounds

The SMA Project is preparing to issue a Request for Proposals (RFP) within the next 30 days for a centralized service facility dedicated to the in vitro testing of potential Spinal Muscular Atrophy (SMA) compounds. This initiative is part of the National Institute for Neurological Disorders and Stroke’s (NINDS) collaborative program aimed at accelerating the development of treatments for SMA, a severe neurodegenerative childhood disease. Interested parties are encouraged to join the SMA Project ListServ to receive immediate notifications about the RFP release, which will also be announced on FedBizOpps. Proposal submission materials will be accessible on the SMA Project’s Open Solicitations webpage, with a deadline set for at least four weeks following the RFP release date. The contract, managed in partnership with Science Applications International Corporation (SAIC), is open to all responsible offerors. It focuses on milestone-driven research to identify effective SMA therapies through rigorous in vitro compound testing. Although specific details such as location and agency contact information are not provided, the solicitation number is JL-19704-2 and was posted on June 29, 2004. This effort emphasizes collaboration and transparency, aiming to accelerate therapeutic development by providing centralized testing resources critical to advancing preclinical research on SMA treatments.